BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Phase II study for safety and efficacy of BEB (Bendamustine, Etoposide, Busulfan) conditioning regimen for ASCT in non-Hodgkin's lymphoma
Lymphoma, Non-Hodgkin
DRUG: Busulfan|DRUG: Etoposide|DRUG: Bendamustine
Progression-free survival, 1 year after ASCT|Progression-free survival, 3 years after ASCT
Overall survival, 1 year and 3 year after ASCT|Complete response rate, 1 year and 3 year after ASCT|Incidence of adverse events, 1 year and 3 year after ASCT
Phase II study for safety and efficacy of BEB (Bendamustine, Etoposide, Busulfan) conditioning regimen for ASCT in non-Hodgkin's lymphoma